Millennium Management LLC Grows Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT)

Millennium Management LLC increased its holdings in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 252.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,329,149 shares of the company's stock after acquiring an additional 951,779 shares during the quarter. Millennium Management LLC owned approximately 1.14% of Applied Therapeutics worth $1,138,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dark Forest Capital Management LP lifted its position in shares of Applied Therapeutics by 54.5% in the 4th quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company's stock worth $46,000 after purchasing an additional 18,949 shares during the period. SG Americas Securities LLC increased its holdings in Applied Therapeutics by 169.0% during the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock valued at $35,000 after buying an additional 25,601 shares during the period. Deutsche Bank AG raised its stake in Applied Therapeutics by 0.7% in the fourth quarter. Deutsche Bank AG now owns 4,468,122 shares of the company's stock worth $3,843,000 after buying an additional 30,520 shares in the last quarter. Ground Swell Capital LLC purchased a new stake in Applied Therapeutics during the fourth quarter worth $27,000. Finally, Intech Investment Management LLC boosted its position in Applied Therapeutics by 176.1% during the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company's stock valued at $45,000 after acquiring an additional 33,567 shares in the last quarter. 98.31% of the stock is currently owned by institutional investors.

Applied Therapeutics Stock Up 1.5%

Shares of APLT traded up $0.01 during mid-day trading on Friday, hitting $0.37. 1,185,579 shares of the company traded hands, compared to its average volume of 3,364,899. The company has a market capitalization of $52.27 million, a PE ratio of -0.23 and a beta of 2.00. The business has a 50 day moving average of $0.39 and a 200 day moving average of $1.10. Applied Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $10.62.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its earnings results on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The company had revenue of $0.00 million during the quarter, compared to analysts' expectations of $0.61 million. As a group, research analysts expect that Applied Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

APLT has been the subject of several recent research reports. Royal Bank of Canada reissued a "sector perform" rating and issued a $1.50 price target on shares of Applied Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen upgraded Applied Therapeutics to a "sell" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $6.10.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.